Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone.

Abstract

Avarol and avarone are two antimitotic and antimutagenic agents that preferentially inhibit proliferation of T-cell leukemia lines in vitro. This report shows that these compounds have a dose-dependent inhibitory effect on the replication of the etiologic agent of acquired immune deficiency syndrome (AIDS), human T-lymphotropic retrovirus (HTLV-III)/lymphadenopathy-associated virus, in human H9 cells in vitro. Both compounds show a significant cytoprotective effect on HTLV-IIIB-infected H9 cells at concentrations as low as 0.1 microgram/ml (0.3 microM). Both avarone and avarol block in a dose-dependent manner the expression of the p24 and p17 gag proteins of HTLV-III in H9 cells after virus infection and block viral replication, as judged by approximately 80% inhibition of reverse transcriptase activity. These results strongly suggest that these compounds may prove to be useful in the treatment of patients with AIDS and AIDS-related complex.

• Authors: P S Sarin, D Sun, A Thornton, W E Müller
• Journal: Journal of the National Cancer Institute (J Natl Cancer Inst) Vol. 78 Issue 4 Pg. 663-6 (Apr 1987) ISSN: 0027-8874 [Print] United States
• PMID: 2435942 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cyclohexenes
• Reverse Transcriptase Inhibitors
• Sesquiterpenes
• avarone
• avarol

Topics

• Acquired Immunodeficiency Syndrome (microbiology)
• Cell Line
• Cyclohexenes
• Cytopathogenic Effect, Viral
• HIV (physiology)
• Humans
• Reverse Transcriptase Inhibitors
• Sesquiterpenes (pharmacology)
• Virus Replication (drug effects)